<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1435" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1435/" /><meta name="ncbi_pagename" content="Alpha-Thalassemia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Alpha-Thalassemia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Alpha-Thalassemia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/12/29" /><meta name="citation_author" content="Raffaella Origa" /><meta name="citation_author" content="Paolo Moi" /><meta name="citation_pmid" content="20301608" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1435/" /><meta name="citation_keywords" content="Hemoglobin Bart Hydrops Fetalis (Hb Bart) Syndrome" /><meta name="citation_keywords" content="Hemoglobin H (HbH) Disease" /><meta name="citation_keywords" content="a-Thalassemia Trait" /><meta name="citation_keywords" content="a-Thalassemia Silent Carrier" /><meta name="citation_keywords" content="Hemoglobin subunit alpha" /><meta name="citation_keywords" content="Hemoglobin subunit zeta" /><meta name="citation_keywords" content="HBA1" /><meta name="citation_keywords" content="HBA2" /><meta name="citation_keywords" content="HBZ" /><meta name="citation_keywords" content="Alpha-Thalassemia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Alpha-Thalassemia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Raffaella Origa" /><meta name="DC.Contributor" content="Paolo Moi" /><meta name="DC.Date" content="2016/12/29" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1435/" /><meta name="description" content="Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome, caused by deletion of all four α-globin genes; and hemoglobin H (HbH) disease, most frequently caused by deletion of three α-globin genes." /><meta name="og:title" content="Alpha-Thalassemia" /><meta name="og:type" content="book" /><meta name="og:description" content="Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome, caused by deletion of all four α-globin genes; and hemoglobin H (HbH) disease, most frequently caused by deletion of three α-globin genes." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1435/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/a-thal/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1435/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C0029E0405B0100000000053601EB.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1435_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1435_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/xlmr/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/alport/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1435_"><span class="title" itemprop="name">Alpha-Thalassemia</span></h1><p class="contrib-group"><span itemprop="author">Raffaella Origa</span>, MD and <span itemprop="author">Paolo Moi</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1435_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1435_ai__"><div class="contrib half_rhythm"><span itemprop="author">Raffaella Origa</span>, MD<div class="affiliation small">Dipartimento di Scienze Mediche e Sanit&#x000e0; Pubblica<br />Universit&#x000e0; degli Studi di Cagliari<br />Ospedale Regionale per le Microcitemie<br />Cagliari, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.acinu@agiro.alleaffar" class="oemail">ti.acinu@agiro.alleaffar</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Paolo Moi</span>, MD<div class="affiliation small">Dipartimento di Scienze Mediche e Sanit&#x000e0; Pubblica<br />Universit&#x000e0; degli Studi di Cagliari<br />Ospedale Regionale per le Microcitemie<br />Cagliari, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.acinu@iomp" class="oemail">ti.acinu@iomp</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 1, 2005</span>; Last Update: <span itemprop="dateModified">December 29, 2016</span>.</p><p><em>Estimated reading time: 33 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="a-thal.Summary" itemprop="description"><h2 id="_a-thal_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Alpha-thalassemia (&#x003b1;-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome, caused by <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of all four &#x003b1;-globin genes; and hemoglobin H (HbH) disease, most frequently caused by deletion of three &#x003b1;-globin genes.</p><ul><li class="half_rhythm"><div>Hb Bart syndrome, the more severe form, is characterized by fetal onset of generalized edema, pleural and pericardial effusions, and severe hypochromic anemia, in the absence of ABO or Rh blood group incompatibility. Additional clinical features include marked hepatosplenomegaly, extramedullary erythropoiesis, hydrocephalus, and cardiac and urogenital defects. Death usually occurs in the neonatal period.</div></li><li class="half_rhythm"><div>HbH disease is characterized by microcytic hypochromic hemolytic anemia, splenomegaly, mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to oxidant drugs and infections.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of Hb Bart syndrome is established in a fetus with the characteristic radiographic and laboratory features. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>HBA1</i> and <i>HBA2</i> that result in <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or inactivation of all four &#x003b1;-globin alleles confirms the diagnosis. The diagnosis of HbH disease is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the characteristic laboratory and clinical features. Identification of biallelic pathogenic variants in <i>HBA1</i> and <i>HBA2</i> that result in deletion or inactivation of three &#x003b1;-globin alleles confirms the diagnosis.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Intrauterine blood transfusions, improved transfusion strategies, and rarely curative hematopoietic stem cell transplant may allow survival of children with Hb Bart syndrome. For HbH disease, occasional red blood cell transfusions may be needed during hemolytic or aplastic crises. Red blood cell transfusions are very rarely needed for severe anemia affecting cardiac function and erythroid expansion that results in severe bone changes and extramedullary erythropoiesis.</p><p><i>Prevention of primary manifestations:</i> Because of the severity of Hb Bart syndrome and the risk for maternal complications, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> and early termination of pregnancies at risk has usually been considered. However, recent advances in intrauterine and postnatal therapy have increased treatment options &#x02013; thus complicating the ethical issues for health care providers and families facing an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> pregnancy.</p><p><i>Prevention of secondary complications:</i> Monitor individuals with HbH disease for hemolytic/aplastic crisis during febrile episodes; in those who require chronic red blood cell transfusions, iron chelation therapy should be instituted; for those who are not red blood cell transfusion dependent, iron chelation with deferasirox can be considered to reduce liver iron concentration.</p><p><i>Surveillance:</i> For HbH disease, hematologic evaluation every six to 12 months; assessment of growth and development in children every six to 12 months; monitoring of iron load with serum ferritin concentration and periodic quantitative measurement of liver iron concentration.</p><p><i>Agents/circumstances to avoid:</i> In HbH disease, inappropriate iron therapy, oxidant drugs such as sulphonamides, and some antimalarials.</p><p><i>Evaluation of relatives at risk:</i> Test the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> as soon as possible after birth for HbH disease so that monitoring can be instituted.</p><p><i>Pregnancy management</i>: Complications reported in pregnant women with HbH disease include worsening anemia, preeclampsia, congestive heart failure, and threatened miscarriage; monitoring for these issues during pregnancy is recommended.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Alpha-thalassemia is usually inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an individual with Hb Bart syndrome has a 25% chance of having Hb Bart syndrome, a 50% chance of having &#x003b1;-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or inactivation <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;), and a 25% chance of being unaffected and not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p><p>At conception, if one parent has &#x003b1;-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) and the other parent is an &#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (1-gene deletion; -&#x003b1;/&#x003b1;&#x003b1;), each sib of an individual with HbH disease has a 25% chance of having HbH disease, a 25% chance of having &#x003b1;-thalassemia trait, a 25% chance of being an &#x003b1;-thalassemia silent carrier, and a 25% chance of being unaffected and not a carrier. Each child of an individual with HbH disease inherits either the two-gene deletion <i>in</i>
<i>cis</i> and has &#x003b1;-thalassemia trait or is an &#x003b1;-thalassemia silent carrier and is thus an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a>; risk to the child of having the disease depends on the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> inherited from the other parent.</p><p>Family members, members of ethnic groups at risk, and gamete donors should be considered for <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a>. Couples who are members of populations at risk for &#x003b1;-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in cis</i> (--/&#x003b1;&#x003b1;) can be identified prior to pregnancy as being at risk of conceiving a fetus with Hb Bart syndrome. Prenatal testing may be carried out for couples who are at high risk of having a fetus with Hb Bart syndrome or for a pregnancy in which one parent is a known &#x003b1;-thalassemia carrier with a two-gene deletion <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) when the other parent is either unknown or unavailable for testing.</p></div></div><div id="a-thal.GeneReview_Scope"><h2 id="_a-thal_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="a-thal.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-thal.Td_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Alpha-Thalassemia (&#x003b1;-Thalassemia)</th></tr><tr><th headers="hd_h_a-thal.Td_1_1_1_1" id="hd_h_a-thal.Td_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype&#x000a0;<sup>1</sup></th><th headers="hd_h_a-thal.Td_1_1_1_1" id="hd_h_a-thal.Td_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Genotype</th></tr></thead><tbody><tr><td headers="hd_h_a-thal.Td_1_1_1_1 hd_h_a-thal.Td_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemoglobin Bart hydrops fetalis (Hb Bart) syndrome</td><td headers="hd_h_a-thal.Td_1_1_1_1 hd_h_a-thal.Td_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Loss of all 4 &#x003b1;-globin genes</td></tr><tr><td headers="hd_h_a-thal.Td_1_1_1_1 hd_h_a-thal.Td_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemoglobin H (HbH) disease</td><td headers="hd_h_a-thal.Td_1_1_1_1 hd_h_a-thal.Td_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Loss of 3 &#x003b1;-globin genes</td></tr><tr><td headers="hd_h_a-thal.Td_1_1_1_1 hd_h_a-thal.Td_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b1;-thalassemia trait</td><td headers="hd_h_a-thal.Td_1_1_1_1 hd_h_a-thal.Td_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Loss of 2 &#x003b1;-globin genes either <i>in cis</i> (--/&#x003b1;&#x003b1;, &#x003b1;<sup>0</sup> <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) or <i>in trans</i> (-&#x003b1;/-&#x003b1;)</td></tr><tr><td headers="hd_h_a-thal.Td_1_1_1_1 hd_h_a-thal.Td_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a></td><td headers="hd_h_a-thal.Td_1_1_1_1 hd_h_a-thal.Td_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Loss of 1 &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (-&#x003b1;/&#x003b1;&#x003b1;, &#x003b1;<sup>+</sup> <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#a-thal.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="a-thal.TF.d.1"><p class="no_margin">In descending order of severity</p></div></dd></dl></div></div></div></div><div id="a-thal.Diagnosis"><h2 id="_a-thal_Diagnosis_">Diagnosis</h2><div id="a-thal.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Alpha-thalassemia (&#x003b1;-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis syndrome (<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of all 4 &#x003b1;-globin genes; --/--), and hemoglobin H disease (most frequently caused by deletion of 3 &#x003b1;-globin genes; --/-&#x003b1;).</p><div id="a-thal.Hemoglobin_Bart_Hydrops_Fetalis_S"><h4>Hemoglobin Bart Hydrops Fetalis Syndrome</h4><p>Hemoglobin Bart hydrops fetalis (Hb Bart) syndrome <b>should be suspected</b> in fetuses with the following ultrasonographic features and/or laboratory features.</p><p><b>Radiographic features</b></p><ul><li class="half_rhythm"><div>An at-risk fetus with increased nuchal thickness, thickened placenta, increased cerebral media artery velocity, and increased cardiothoracic ratio on ultrasonography examination at 13 to 14 weeks' gestation</div></li><li class="half_rhythm"><div>A fetus with generalized edema, ascites, and pleural and pericardial effusions detected by ultrasonography examination at 22 to 28 weeks' gestation</div></li></ul><p><b>Laboratory features</b></p><ul><li class="half_rhythm"><div>Red blood cell indices: severe macrocytic hypochromic anemia, in the absence of ABO or Rh blood group incompatibility (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_indiv/?report=objectonly" target="object" rid-figpopup="figathalTredbloodcellindicesinindiv" rid-ob="figobathalTredbloodcellindicesinindiv">Table 1</a>)</div></li><li class="half_rhythm"><div>Reticulocytosis: variable; may be more than 60%</div></li><li class="half_rhythm"><div>Peripheral blood smear with large, hypochromic red cells and severe anisopoikilocytosis</div></li></ul></div><div id="a-thal.Hemoglobin_H_Disease"><h4>Hemoglobin H Disease</h4><p>Hemoglobin H (HbH) disease <b>should be suspected</b> in an infant or child with the following <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> results, clinical features, and/or laboratory features.</p><p><b>Newborn screening.</b> Hb Bart &#x0003e;15% at birth</p><p>Note: (1) Newborn screening for sickle cell disease offered by several states/countries may detect Hb Bart in the newborn with &#x003b1;-thalassemia (see <a href="http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/nbsdisorders.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">National Newborn Screening Status Report</a>). (2) Reference ranges may vary among laboratories performing <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> (3) Low concentrations of Hb Bart (1%-8%) are indicative of the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> states and usually do not need further evaluation.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Hepatosplenomegaly</div></li><li class="half_rhythm"><div>Mild thalassemia-like bone changes (e.g., hypertrophy of the maxilla, bossing of the skull, and prominence of the malar eminences)</div></li><li class="half_rhythm"><div>Mild jaundice</div></li></ul><p><b>Laboratory features</b></p><ul><li class="half_rhythm"><div>Red blood cell indices: mild-to-moderate (rarely severe) microcytic hypochromic hemolytic anemia (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_indiv/?report=objectonly" target="object" rid-figpopup="figathalTredbloodcellindicesinindiv" rid-ob="figobathalTredbloodcellindicesinindiv">Table 1</a>)</div></li><li class="half_rhythm"><div>Moderate reticulocytosis: 3%-6%</div></li><li class="half_rhythm"><div>Peripheral blood smear with anisopoikilocytosis, and very rare nucleated red blood cells (i.e., erythroblasts)</div></li><li class="half_rhythm"><div>Red blood cell supravital stain showing HbH inclusions (&#x003b2;<sub>4</sub> tetramers) in 5% to 80% of erythrocytes following incubation of fresh blood smears with 1% brilliant cresyl blue for one to three hours</div></li></ul><div id="a-thal.T.red_blood_cell_indices_in_indiv" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Red Blood Cell Indices in Individuals with Hemoglobin Bart Hydrops Fetalis and Hemoglobin H Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_indiv/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.T.red_blood_cell_indices_in_indiv_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_1" style="text-align:left;vertical-align:middle;">Red Blood Cell Indices</th><th id="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Normal</th><th id="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Affected</th></tr><tr><th headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2" id="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Male</th><th headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2" id="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Female</th><th headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3" id="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemoglobin Bart hydrops fetalis&#x000a0;<sup>1</sup></th><th headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3" id="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemoglobin H disease&#x000a0;<sup>2</sup></th></tr></thead><tbody><tr><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mean corpuscular volume (MCV, fl)</b></td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">89.1&#x000b1;5.01</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">87.6&#x000b1;5.5</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">136&#x000b1;5.1</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Children: 56&#x000b1;5<br />Adults: 61&#x000b1;4</td></tr><tr><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mean corpuscular hemoglobin (MCH, pg)</b></td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30.9&#x000b1;1.9</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30.2&#x000b1;2.1</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">31.9&#x000b1;9</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18.4&#x000b1;1.2</td></tr><tr><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hemoglobin (Hb, g/dL)</b></td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15.9&#x000b1;1.0</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14.0&#x000b1;0.9</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-8</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_indiv_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Male: 10.9&#x000b1;1.0<br />Female: 9.5&#x000b1;0.8</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="a-thal.TF.1.1"><p class="no_margin"><a class="bk_pop" href="#a-thal.REF.vaeusorn.1985">Vaeusorn et al [1985]</a></p></div></dd><dt>2. </dt><dd><div id="a-thal.TF.1.2"><p class="no_margin"><a class="bk_pop" href="#a-thal.REF.galanello.1992.1">Galanello et al [1992]</a></p></div></dd></dl></div></div></div></div><div id="a-thal.Hemoglobin_Analysis"><h4>Hemoglobin Analysis</h4><p>Qualitative and quantitative hemoglobin (Hb) analysis (by cellulose acetate electrophoresis, weak-cation high-performance liquid chromatography [HPLC], and supplemental techniques such as <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> and citrate agar electrophoresis) identifies the amount and type of Hb present. The Hb pattern in &#x003b1;-thalassemia varies by &#x003b1;-thalassemia type (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.hemoglobin_patterns_in_alphatha/?report=objectonly" target="object" rid-figpopup="figathalThemoglobinpatternsinalphatha" rid-ob="figobathalThemoglobinpatternsinalphatha">Table 2</a>). The Hb types most relevant to &#x003b1;-thalassemia are:</p><ul><li class="half_rhythm"><div>Hemoglobin A (HbA). Two &#x003b1;-globin chains and two &#x003b2;-globin chains (&#x003b1;<sub>2</sub>&#x003b2;<sub>2</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin F (HbF). Two &#x003b1;-globin chains and two &#x003b3;-globin chains (&#x003b1;<sub>2</sub>&#x003b3;<sub>2</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin Bart (Hb Bart). Four &#x003b3;-globin chains (&#x003b3;<sub>4</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin H (HbH). Four &#x003b2;-globin chains (&#x003b2;<sub>4</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin A2 (HbA2). Two &#x003b1;-globin chains and two &#x003b4;-globin chains (&#x003b1;<sub>2</sub>&#x003b4;<sub>2</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin Portland. Two &#x003b6;-globin chains and two &#x003b3;-globin chains (&#x003b6;<sub>2</sub>&#x003b3;<sub>2</sub>)</div></li></ul><div id="a-thal.T.hemoglobin_patterns_in_alphatha" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Hemoglobin Patterns in Alpha-Thalassemia (Age &#x0003e;12 Months)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.T.hemoglobin_patterns_in_alphatha/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.T.hemoglobin_patterns_in_alphatha_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1" style="text-align:left;vertical-align:middle;">Hemoglobin Type</th><th id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_2" style="text-align:left;vertical-align:middle;">Normal</th><th id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Affected</th></tr><tr><th headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3" id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Hb Bart hydrops fetalis syndrome&#x000a0;<sup>1</sup></th><th headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3" id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HbH disease&#x000a0;<sup>2</sup></th></tr></thead><tbody><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>HbA</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%-98%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%-90%</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>HbF</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1.0%</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hb Bart</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">85%-90%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-5%</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>HbH</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.8%-40%</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>HbA2</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-3%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2.0%</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hb Portland</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%-15%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_3 hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="a-thal.TF.2.1"><p class="no_margin">Deletion or inactivation of all four &#x003b1;-globin chains makes it impossible to assemble HbF and HbA. Fetal blood contains mainly Hb Bart (&#x003b3;<sub>4</sub>) and 10%-15% of the embryonic hemoglobin Portland (&#x003b6;<sub>2</sub>&#x003b3;<sub>2</sub>).</p></div></dd><dt>2. </dt><dd><div id="a-thal.TF.2.2"><p class="no_margin">Deletion or inactivation of three &#x003b1;-globin chains</p></div></dd></dl></div></div></div><p>See <a href="#a-thal.Genetic_Counseling">Genetic Counseling</a> for information about hematologic testing to identify alpha-thalassemia trait and alpha-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status.</p></div></div><div id="a-thal.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <b>hemoglobin Bart hydrops fetalis syndrome is established</b> in a fetus with the above <a href="#a-thal.Hemoglobin_Bart_Hydrops_Fetalis_S">ultrasonographic and laboratory features</a>. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in both <i>HBA1</i> and <i>HBA2</i> that results in <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or inactivation of all four &#x003b1;-globin alleles (e.g., 2 &#x003b1;-globin deletions in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state; --/--) on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_indiv/?report=objectonly" target="object" rid-figpopup="figathalTredbloodcellindicesinindiv" rid-ob="figobathalTredbloodcellindicesinindiv">Table 1</a>) confirms the diagnosis and allows for family studies.</p><p>The diagnosis of <b>hemoglobin H disease is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above <a href="#a-thal.Hemoglobin_H_Disease">clinical and laboratory features</a>. Identification of pathogenic variants in <i>HBA1</i> and <i>HBA2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_indiv/?report=objectonly" target="object" rid-figpopup="figathalTredbloodcellindicesinindiv" rid-ob="figobathalTredbloodcellindicesinindiv">Table 1</a>) that results in <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or inactivation of three &#x003b1;-globin genes (e.g., a 2 &#x003b1;-globin-deletion <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> <i>in trans</i> with a single &#x003b1;-globin-deletion allele; --/-&#x003b1;<sup>3.7</sup>) confirms the diagnosis and allows for family studies.</p><p>See <a class="figpopup" href="/books/NBK1435/figure/a-thal.F1/?report=objectonly" target="object" rid-figpopup="figathalF1" rid-ob="figobathalF1">Figure 1</a> for a diagnostic algorithm for hemoglobinopathies.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figathalF1" co-legend-rid="figlgndathalF1"><a href="/books/NBK1435/figure/a-thal.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figathalF1" rid-ob="figobathalF1"><img class="small-thumb" src="/books/NBK1435/bin/a-thal-Image001.gif" src-large="/books/NBK1435/bin/a-thal-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndathalF1"><h4 id="a-thal.F1"><a href="/books/NBK1435/figure/a-thal.F1/?report=objectonly" target="object" rid-ob="figobathalF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Diagnostic algorithm for hemoglobinopathies </p></div></div><p>Molecular testing approaches can include <b>targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> analysis for common deletions</b>, <b><a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a></b>, and <b>deletion analysis</b> of <i>HBA1</i>, <i>HBA2</i> and the HS-40 regulatory region.</p><p><b>Targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> analysis</b> for common deletions of <i>HBA1</i>and <i>HBA2</i> can be performed first.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Common two &#x003b1;-globin-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions (&#x003b1;&#x000ba;-<a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>)</b></div><ul><li class="half_rhythm"><div>The Southeast Asian <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (&#x02212;&#x02212;<sup>SEA</sup>)</div></li><li class="half_rhythm"><div>The Filipino <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (&#x02212;&#x02212;<sup>FIL</sup>)</div></li><li class="half_rhythm"><div>The Mediterranean <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (&#x02212;&#x02212;<sup>MED</sup>)</div></li></ul><div class="half_rhythm">Note: (1) These common deletions are typically founder variants (see <a href="#a-thal.Prevalence">Prevalence</a>). (2) More than 20 different deletions ranging from ~6 kb to &#x0003e;300 kb and removing both &#x003b1;-globin genes (and sometimes embryonic <i>HBZ</i>) have been reported.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Common single &#x003b1;-globin-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions (&#x003b1;<sup>+</sup>-<a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>)</b></div><ul><li class="half_rhythm"><div>The 3.7-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (-&#x003b1;<sup>3.7</sup>) deletion</div></li><li class="half_rhythm"><div>The 4.2-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (-&#x003b1;<sup>4.2</sup>) deletion</div></li></ul><div class="half_rhythm">Note: In addition to these two common deletions, rare deletions involving a single &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been reported.</div></li></ul><p><b>Sequence analysis</b> of <i>HBA1</i> and <i>HBA2</i> can be performed next if a common <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> was not identified.</p><p>Note: Non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or "trait" <i>HBA2</i> variants are designated as (&#x003b1;<sup>ND</sup>&#x003b1;/) or (&#x003b1;<sup>T</sup>&#x003b1;/); variants in <i>HBA1</i> are designated as (&#x003b1;&#x003b1;<sup>ND</sup> /) or (&#x003b1;&#x003b1;<sup>T</sup> /) (see <a href="#a-thal.Molecular_Genetics">Molecular Genetics</a>).</p><p><b>Deletion analysis</b> of <i>HBA1</i>, <i>HBA2</i>, and the HS-40 regulatory region located 40 kb upstream from the &#x003b1;-globin cluster can be performed next to detect uncommon deletions associated with &#x003b1;-thalassemia if pathogenic variants have not been identified by targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> testing or <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p><b>Further testing</b> for genes associated with genetic disorders similar to &#x003b1;-thalassemia, such as <i>ATRX</i> and <i>HBB</i> (see <a href="#a-thal.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered if clinically indicated.</p><div id="a-thal.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Alpha-Thalassemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Genes&#x000a0;<sup>1</sup></th><th id="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA1</i> and <i>HBA2</i></td><td headers="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted common <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~85%</td></tr><tr><td headers="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5,&#x000a0;6</sup></td><td headers="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~15%</td></tr><tr><td headers="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion analysis&#x000a0;<sup>7</sup></td><td headers="hd_h_a-thal.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02264;5%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="a-thal.TF.3.1"><p class="no_margin">See <a href="/books/NBK1435/#a-thal.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="a-thal.TF.3.2"><p class="no_margin">See <a href="#a-thal.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="a-thal.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#a-thal.REF.harteveld.2014.1">Harteveld [2014]</a></p></div></dd><dt>4. </dt><dd><div id="a-thal.TF.3.4"><p class="no_margin">Targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> assays can detect specific deletions within the &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster. The method commonly used to identify targeted deletion is GAP-<a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>.</p></div></dd><dt>5. </dt><dd><div id="a-thal.TF.3.5"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>6. </dt><dd><div id="a-thal.TF.3.6"><p class="no_margin">Targeted analysis for known pathogenic variants (<a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a>) may also be used. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>-specific <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>, allele-specific oligonucleotide testing, and restriction fragment length <a class="def" href="/books/n/gene/glossary/def-item/polymorphism/">polymorphism</a> (RFLP) testing.</p></div></dd><dt>7. </dt><dd><div id="a-thal.TF.3.7"><p class="no_margin">Methods that may be used to detect rare or unknown deletions include: Southern blotting, <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR and MPLA. The same methods may be used to detect duplications of the &#x003b1;-cluster. Deletion analysis should include the HS-40 regulatory region located 40 kb upstream from the &#x003b1;-globin cluster.</p></div></dd></dl></div></div></div></div></div><div id="a-thal.Clinical_Characteristics"><h2 id="_a-thal_Clinical_Characteristics_">Clinical Characteristics</h2><div id="a-thal.Clinical_Description"><h3>Clinical Description</h3><p>The clinically significant phenotypes of alpha-thalassemia (&#x003b1;-thalassemia) are hemoglobin Bart hydrops fetalis (Hb Bart) syndrome and hemoglobin H (HbH) disease. The severity of the &#x003b1;-thalassemia syndromes depends on the extent of &#x003b1;-globin chain defect (see <a href="#a-thal.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</p><p><b>Hb Bart syndrome</b> is the most severe clinical condition related to &#x003b1;-thalassemia. Affected fetuses are either delivered stillborn at 30 to 40 weeks&#x02019; gestation or die soon after birth.</p><p>The main clinical features are generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Notably, red cells with Hb Bart have an extremely high oxygen affinity and are incapable of effective oxygen delivery. The blood smear shows large hypochromic macrocytes and numerous nucleated red cells. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common.</p><p>Retardation in brain growth, hydrocephalus, cardiovascular deformities, and urogenital defects have been reported.</p><p>A very small number of individuals survive following intrauterine transfusions and repeated frequent transfusions after birth.</p><p>Maternal complications during pregnancy commonly include: preeclampsia, polyhydramnios or oligohydramnios, antepartum hemorrhage, and premature delivery.</p><p><b>HbH disease.</b> The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of HbH disease varies. Although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual.</p><p>The majority of individuals show microcytic hypochromic hemolytic anemia (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_indiv/?report=objectonly" target="object" rid-figpopup="figathalTredbloodcellindicesinindiv" rid-ob="figobathalTredbloodcellindicesinindiv">Table 1</a>), enlargement of the spleen and less commonly of the liver, mild jaundice, and sometimes mild-to-moderate thalassemia-like skeletal changes (e.g., hypertrophy of the maxilla, bossing of the skull, and prominence of the malar eminences) that affects the facial features. Leg ulcers are rare.</p><p>Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to oxidant drugs and infections. Rarely, aplastic crisis due to infection of parvovirus B19 may occur in individuals with HbH disease.</p><p>While the majority of individuals with HbH disease have minor disability, some are severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, requiring regular blood transfusions; in very rare cases hydrops fetalis is present [<a class="bk_pop" href="#a-thal.REF.lorey.2001.72">Lorey et al 2001</a>, <a class="bk_pop" href="#a-thal.REF.chui.2003.791">Chui et al 2003</a>].</p><p>Significant iron overload is uncommon but has been reported in older individuals, usually as a result of repeated blood transfusions or increased iron absorption [<a class="bk_pop" href="#a-thal.REF.taher.2012.970">Taher et al 2012</a>].</p></div><div id="a-thal.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of the &#x003b1;-thalassemia syndromes depends on the degree of &#x003b1;-globin chain deficiency relative to &#x003b2;-globin production. The correlation between &#x003b1;-thalassemia pathogenic variants, &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> levels, &#x003b1;-globin synthesis, and clinical manifestations of &#x003b1;-thalassemia is well documented.</p><p><b>Hb Bart syndrome</b></p><ul><li class="half_rhythm"><div>Most often caused by large deletions on both alleles (&#x003b1;-globin --/--)</div></li><li class="half_rhythm"><div>Rarely, an individual with Hb Bart syndrome will have a non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variant.</div></li></ul><p><b>HbH disease</b></p><ul><li class="half_rhythm"><div>Most often caused by a large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> <i>in trans</i> with a single &#x003b1;-globin-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletion (--/-&#x003b1;) or other non-deletion <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> variant (--/&#x003b1;<sup>ND</sup>&#x003b1; or --/&#x003b1;&#x003b1;<sup>ND</sup>)</div></li><li class="half_rhythm"><div>Individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the Constant Spring variant (&#x003b1;<sup>CS</sup>&#x003b1;/&#x003b1;<sup>CS</sup>&#x003b1;) or <i>HBA2</i> poly (A) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may have HbH disease.</div></li><li class="half_rhythm"><div>Individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for highly unstable &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> variants may have HbH disease.</div></li><li class="half_rhythm"><div>Rarely, HbH disease is caused by a <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> HS40 <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> [<a class="bk_pop" href="#a-thal.REF.coelho.2010.147">Coelho et al 2010</a>, <a class="bk_pop" href="#a-thal.REF.sollaino.2010.2193">Sollaino et al 2010</a>].</div></li></ul><p><b>Alpha-thalassemia trait</b></p><ul><li class="half_rhythm"><div class="half_rhythm">May result from <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or inactivation of two &#x003b1;-globin genes <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;)</div></li><li class="half_rhythm"><div class="half_rhythm">May result from <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of a single <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> on both alleles (e.g., -&#x003b1;<sup>3.7</sup>/-&#x003b1;<sup>3.7</sup>)</div></li><li class="half_rhythm"><div class="half_rhythm">May result from non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variants <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> <i>HBA2</i>(&#x003b1;<sup>ND</sup>&#x003b1;/&#x003b1;&#x003b1;)</div><div class="half_rhythm">Individuals with alpha-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) have slightly lower RBC indices than individuals with a two-gene deletion <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a>. The most severe alleles in descending order are: two-gene deletion <i>in</i>
<i>cis</i>, non-deletion <i>HBA2</i> variant, -&#x003b1;<sup>4.2</sup>, -&#x003b1;<sup>3.7</sup> (because of compensatory increase of &#x003b1;-globin production from the remaining <i>HBA1</i>), and non-deletion <i>HBA1</i> variant. For the -&#x003b1;<sup>4.2</sup> deletion, evidence is inconclusive for a compensatory increase in the expression of the remaining &#x003b1;-globin gene.</div></li><li class="half_rhythm"><div class="half_rhythm">The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be modified by triplication or quadruplication of the &#x003b1;-globin genes on one <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a>.</div></li></ul><p><b>Alpha-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a></b></p><ul><li class="half_rhythm"><div>Results from <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of one &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (-&#x003b1;/&#x003b1;&#x003b1;) or inactivation of <i>HBA1</i> (&#x003b1;&#x003b1;<sup>ND</sup>/&#x003b1;&#x003b1;)</div></li><li class="half_rhythm"><div>The genotypes causing silent alpha-thalassemia may have a completely silent hematologic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> or may present with a moderate thalassemia-like hematologic picture (i.e., reduced MCV and MCH, but normal HbA2 and HbF), similar to individuals with &#x003b1;-thalassemia trait.</div></li></ul></div><div id="a-thal.Nomenclature"><h3>Nomenclature</h3><p>The &#x003b1;-thalassemias have been classified on the basis of the total globin production from each of the two &#x003b1;-globin genes, <i>HBA1</i> and <i>HBA2</i>, present on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 16:</p><ul><li class="half_rhythm"><div>When both &#x003b1;-globin genes on a <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> are deleted or inactivated, the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is referred to as &#x003b1;<sup>0</sup> (no output of &#x003b1;-globin from the chromosome). An individual with the <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> --/&#x003b1;&#x003b1; is referred to as an &#x003b1;<sup>0</sup> <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li><li class="half_rhythm"><div>When one &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> on a <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> is deleted or inactivated by a non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variant the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is called &#x003b1;<sup>+</sup> (some &#x003b1;-globin is produced). An individual with the <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> -&#x003b1;/&#x003b1;&#x003b1; is referred to as an &#x003b1;<sup>+</sup> <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li></ul><p>Alpha-thalassemias have also been classified based on the number of globin genes that are missing or abnormal: alpha-thalassemia 1 (-&#x003b1;/&#x003b1;&#x003b1;, &#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>); alpha-thalassemia 2 (-&#x003b1;/-&#x003b1; or --/&#x003b1;&#x003b1;, &#x003b1;-thalassemia trait) [<a class="bk_pop" href="#a-thal.REF.lehmann.1984.552">Lehmann &#x00026; Carrell 1984</a>].</p></div><div id="a-thal.Prevalence"><h3>Prevalence</h3><p>Since the early 1960s, prevalence of &#x003b1;-thalassemia has been determined in several populations using the percent of Hb Bart in cord blood. However, because not all newborns with &#x003b1;-thalassemia (mainly &#x003b1;-thalassemia silent carriers) have increased Hb Bart, the prevalence of &#x003b1;-thalassemia derived from this measure may be underestimated.</p><p>More precise data have been obtained using molecular testing. For detailed references for the frequency of &#x003b1;-thalassemia in each population, see <a class="bk_pop" href="#a-thal.REF.piel.2014.1908">Piel &#x00026; Weatherall [2014]</a>.</p><div id="a-thal.Africa"><h4>Africa</h4><p>The highest <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> (0.30-0.40) of the -&#x003b1;<sup>3.7</sup>allele has been observed in the equatorial belt including Nigeria, Ivory Coast, and Kenya.</p><p>The two &#x003b1;-globin-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) has been reported very rarely in North Africa and in the African American population.</p></div><div id="a-thal.The_Mediterranean"><h4>The Mediterranean</h4><p>Alpha-thalassemia trait caused by -&#x003b1;<sup>3.7</sup>/-&#x003b1;<sup>3.7</sup> is common, with the highest <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> reported in Sardinia (0.18) and the lowest in Spain.</p><p>The two &#x003b1;-globin-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) is very rare (0.002); thus, Hb Bart hydrops fetalis is only rarely reported.</p><p>A remarkable aspect of &#x003b1;-thalassemia variants identified in the Mediterranean population is the heterogeneity of variants, particularly the non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variants.</p></div><div id="a-thal.The_Arabian_Peninsula"><h4>The Arabian Peninsula</h4><p>Frequency of the -&#x003b1;<sup>3.7</sup><a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (causing &#x003b1;-thalassemia trait) varies from 0.01 to 0.67, with the highest values being observed in Oman.</p><p>The two &#x003b1;-globin-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) is extremely rare.</p></div><div id="a-thal.India"><h4>India</h4><p>Alpha-thalassemia trait reaches very high <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> (0.35-0.92) in the Indian tribal population of Andra Pradesh; in other tribes, the frequency is much lower (0.03-0.12). Both the -&#x003b1;<sup>3.7</sup>allele and the -&#x003b1;<sup>4.2</sup>allele variably contribute to incidence of &#x003b1;-thalassemia trait.</p><p>The two &#x003b1;-globin-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) is very rare.</p></div><div id="a-thal.Southeast_Asia"><h4>Southeast Asia</h4><p>Alpha<sup>0</sup>-thalassemia alleles (&#x02212;&#x02212;<sup>SEA</sup>, &#x02212;&#x02212;<sup>THAI</sup>, &#x02212;&#x02212;<sup>FIL</sup>) and &#x003b1;<sup>+</sup>-thalassemia alleles (-&#x003b1;) are very common, causing a major public health burden.</p><p>Alpha-thalassemia caused by Hb<sup>Constant Spring</sup> (Hb<sup>CS</sup>) alleles is also common.</p><p>The incidence of Hb Bart hydrops fetalis is expected to be between 0.5 and 5 per 1000 births and HbH disease between 4 and 20 per 1000 births.</p></div><div id="a-thal.Oceania"><h4>Oceania</h4><p>The distribution of &#x003b1;-thalassemia, extensively studied by DNA-based methods, follows a pattern consistent with the degree of malaria endemicity. The prevalence of &#x003b1;<sup>-</sup>-thalassemia is low in the highlands and high in the coastal areas and the lowlands where malaria is hyperendemic.</p><p>Some alpha-thalassemias have unusual mutation mechanisms; for example, some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals on the island of Vanuatu who have normal &#x003b1;-globin genes without deletions or variants have a variant in a regulatory element that creates a GATA-1 site and activates a cryptic promoter [<a class="bk_pop" href="#a-thal.REF.de_gobbi.2006.1215">De Gobbi et al 2006</a>].</p><p>The two &#x003b1;-globin-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in cis</i> (--/&#x003b1;&#x003b1;) is very rare.</p></div></div></div><div id="a-thal.Genetically_Related_Allelic_Disor"><h2 id="_a-thal_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p><b>Alpha-thalassemia/intellectual disability syndrome, <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 16-related</b> (ATR-16 syndrome; OMIM <a href="http://omim.org/entry/141750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">141750</a>), a <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion-syndrome/">contiguous gene deletion syndrome</a>, results from a large terminal deletion of the distal short arm of chromosome 16 from 16p13.3, which includes <i>HBA1</i> and <i>HBA2</i> and additional flanking genes. Among the few reported individuals with deletion of 16p (without deletion or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of other <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> material), microcephaly and short stature were variable; IQ ranged from 53 to 76 [<a class="bk_pop" href="#a-thal.REF.lindor.1997.451">Lindor et al 1997</a>, <a class="bk_pop" href="#a-thal.REF.gibson.2008.225">Gibson et al 2008</a>]. Facial features are distinctive; <i>talipes equinovarus</i> (clubfoot) is common, as are hypospadias and cryptorchidism in males [<a class="bk_pop" href="#a-thal.REF.lindor.1997.451">Lindor et al 1997</a>]. Typically, hematologic features are those of the &#x003b1;-thalassemia trait reflecting deletion of <i>HBA1</i> and <i>HBA2</i> in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration (i.e., --/&#x003b1;&#x003b1;). While routine <a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a> studies may be sufficient to identify the deletion, in some instances cryptic subtelomeric deletions are detected only with subtelomeric <a class="def" href="/books/n/gene/glossary/def-item/fish/">FISH</a> studies, MLPA, or <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> [<a class="bk_pop" href="#a-thal.REF.harteveld.2007.283">Harteveld et al 2007</a>, <a class="bk_pop" href="#a-thal.REF.gibson.2008.225">Gibson et al 2008</a>]. The deletion may be <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> or inherited from a parent who carries a balanced chromosome rearrangement.</p><p><b>Acquired &#x003b1;-thalassemia (&#x003b1;-thalassemia-myelodysplastic syndrome [ATMDS]).</b> In the context of a clonal myeloid disorder such as myelodysplastic syndrome, somatic variants causing an acquired form of &#x003b1;-thalassemia HbH disease in individuals who were previously hematologically normal may arise [<a class="bk_pop" href="#a-thal.REF.steensma.2005.443">Steensma et al 2005</a>]. Red cell indices are usually hypochromic and microcytic, in contrast to the normocytic or macrocytic indices typical of myelodysplastic syndrome. Although most cases of ATMDS have been linked to pathogenic variants in <i>ATRX</i> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> [<a class="bk_pop" href="#a-thal.REF.gibbons.2003.446">Gibbons et al 2003</a>, <a class="bk_pop" href="#a-thal.REF.steensma.2004a.2019">Steensma et al 2004a</a>], acquired deletions of chromosome 16p may be causative [<a class="bk_pop" href="#a-thal.REF.steensma.2004b.1518">Steensma et al 2004b</a>]. For unknown reasons, some individuals with myeloid disorders have small amounts (&#x0003c;1%) of HbH.</p><p><a href="/books/n/gene/xlmr/"><b>Alpha-thalassemia X-linked intellectual disability syndrome</b></a> is NOT an allelic disorder (see <a href="#a-thal.Differential_Diagnosis">Differential Diagnosis</a>).</p></div><div id="a-thal.Differential_Diagnosis"><h2 id="_a-thal_Differential_Diagnosis_">Differential Diagnosis</h2><div id="a-thal.Hydrops_Fetalis"><h3>Hydrops Fetalis</h3><p>Hydrops fetalis is associated with many conditions in addition to Hb Bart, including immune-related disorders (e.g., alloimmune hemolytic disease, Rh isoimmunization), fetal cardiac anomalies, chromosomal abnormalities, fetal infections, genetic disorders, and maternal and placental disorders. The combination of a hydropic fetus with a very high proportion of Hb Bart, however, is found in no other condition.</p></div><div id="a-thal.Hemoglobin_H_HbH_Disease"><h3>Hemoglobin H (HbH) Disease</h3><p><b>Hemolytic anemias.</b> HbH disease can be distinguished from other hemolytic anemias by: (1) microcytosis, which is uncommon in other forms of hemolytic anemia; (2) the fast-moving band (HbH) on hemoglobin electrophoresis; (3) the presence of inclusion bodies (precipitated HbH) in red blood cells after supravital stain; and (4) absence of morphologic or enzymatic changes characteristic of other forms of inherited hemolytic anemia (e.g., hereditary spherocytosis/elliptocytosis, G6PD deficiency). See <a href="/books/n/gene/epb42-spherocytosis/"><i>EPB42</i>-Related Hereditary Spherocytosis</a>.</p><p><a href="/books/n/gene/xlmr/"><b>Alpha-thalassemia X-linked intellectual disability (ATRX) syndrome</b></a> is characterized by distinctive craniofacial features, genital anomalies, severe developmental delays, hypotonia, intellectual disability, and mild-to-moderate anemia secondary to alpha-thalassemia. Craniofacial abnormalities include small head circumference, telecanthus or widely spaced eyes, short nose, tented vermilion of the upper lip, and thick or everted vermilion of the lower lip with coarsening of the facial features over time. Although all individuals with ATRX syndrome have a normal 46,XY <a class="def" href="/books/n/gene/glossary/def-item/karyotype/">karyotype</a>, genital anomalies range from hypospadias and undescended testicles to severe hypospadias and ambiguous genitalia, to normal-appearing female genitalia. Global developmental delays are evident in infancy and some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals never walk independently or develop significant speech. Affected individuals do not reproduce. ATRX syndrome is caused by mutation of <i>ATRX</i> and inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p><p>An unknown percent of 46,XY individuals with ATRX syndrome have a mild form of HbH disease, evident as hemoglobin H inclusions (&#x003b2;<sub>4</sub> tetramers) in erythrocytes following incubation of fresh blood smears with 1% brilliant cresyl blue (BCB). In ATRX syndrome, the &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> cluster and the HS-40 regulatory region of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 16 are structurally intact.</p><p>Acquired variants in <i>ATRX</i> can arise in myelodysplastic syndrome and cause an acquired form of HbH disease (see <a href="#a-thal.Genetically_Related_Allelic_Disor">Genetically Related Disorders</a>, <b>Acquired &#x003b1;-thalassemia</b>).</p></div><div id="a-thal.Carrier_States___Thalassemia_and"><h3>Carrier States (&#x003b1;&#x000ba;-Thalassemia and &#x003b1;+-Thalassemia)</h3><p><a href="/books/n/gene/b-thal/"><b>Beta-thalassemia</b></a><b>.</b> Microcytosis and hypochromia are present in &#x003b1;&#x000ba;-thalassemia carriers, hematologically manifesting &#x003b1;<sup>+</sup>-thalassemia carriers, and &#x003b2;-thalassemia carriers; &#x003b2;-thalassemia carriers, however, are distinguished by a high percent of HbA2.</p><p><b>Iron deficiency anemia.</b> Alpha-thalassemia trait can be confused with iron-deficiency anemia because MCV and MCH are lower than normal in both conditions. However, in iron deficiency anemia, the red blood cell count is decreased, while it is usually increased in &#x003b1;<sup>0</sup>-thalassemia carriers. Though some overlap with &#x003b1;-thalassemia <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> states exists, individuals with iron deficiency anemia show a marked increase in red blood cell distribution width (RDW), a quantitative measure of RBC anisocytosis. The RDW is usually normal or close to normal in thalassemia. The determination of the RBC zinc protoporphyrin concentration and iron studies (serum iron concentration, transferrin saturation) can be used to diagnose iron deficiency anemia with certainty. Iron deficiency and thalassemia can coexist, complicating diagnosis.</p></div></div><div id="a-thal.Management"><h2 id="_a-thal_Management_">Management</h2><p>In 2013, the Thalassemia International Federation published <a href="https://www.ncbi.nlm.nih.gov/books/NBK190453/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Guidelines for the Management of Non Transfusion-Dependent Thalassemia (NTDT)</a>, including beta-thalassemia intermedia, HbH disease and HbE/beta-thalassemia. Guidelines for the management of HbH disease with hemolytic crisis have been developed [<a class="bk_pop" href="#a-thal.REF.fucharoen.2009">Fucharoen &#x00026; Viprakasit 2009</a>] (<a href="http://asheducationbook.hematologylibrary.org/content/2009/1/26.long" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><div id="a-thal.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with alpha-thalassemia (&#x003b1;-thalassemia), the following <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>-based evaluations are recommended:</p><p><b>Hemoglobin Bart hydrops fetalis (Hb Bart) syndrome.</b> See <a href="#a-thal.Prenatal_Testing_and_Preimplantat">Prenatal Testing and Preimplantation Genetic Diagnosis</a>.</p><p><b>Hemoglobin H (HbH) disease</b></p><ul><li class="half_rhythm"><div>Differentiation of <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (mild) from non-deletion (moderate-to-severe) forms of HbH disease by appropriate <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>HBA1</i> and <i>HBA2</i> is important at presentation because of varying severity.</div></li><li class="half_rhythm"><div>Consider referral to a hematologist.</div></li><li class="half_rhythm"><div>Consider consultation with a clinical geneticist and/or genetic counselor.</div></li></ul></div><div id="a-thal.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Hb Bart syndrome</b> was previously considered a universally fatal condition, however, its prognosis is shifting because of <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>, intrauterine blood transfusions, improved transfusion strategies, and (rarely) curative hematopoietic stem cell transplant [<a class="bk_pop" href="#a-thal.REF.pecker.2017.151">Pecker et al 2017</a>]. Although the Thalassemia International Guidelines recommend a transfusion strategy similar to &#x003b2;-thalassemia for these individuals; however, no reports on optimal transfusion management exist [<a class="bk_pop" href="#a-thal.REF.amid.2016.1208">Amid et al 2016</a>]. Because few children with Hb Bart syndrome survive, clinical trials to assess these treatment approaches are lacking.</p><p>The advances in intrauterine and postnatal therapy have resulted in ethical dilemmas for the family and health care provider.</p><p><b>HbH disease.</b> Most individuals with HbH disease are clinically well and survive without any treatment.</p><ul><li class="half_rhythm"><div>Occasional red blood cell transfusions may be needed if the hemoglobin level suddenly drops because of hemolytic or aplastic crises.</div></li><li class="half_rhythm"><div>Chronic red blood cell transfusions should be considered in selected individuals only. Clear indications for red blood cell transfusions are severe anemia affecting cardiac function and massive erythroid expansion, resulting in severe bone changes and extramedullary erythropoiesis. Note: These events are quite rare in HbH disease.</div></li><li class="half_rhythm"><div>Iron chelation therapy may be needed in individuals with iron loading caused by regular blood transfusion, inappropriate iron therapy, or abnormal iron absorption.</div></li><li class="half_rhythm"><div>Splenectomy should be performed only in individuals with massive splenomegaly or hypersplenism; the associated risks for severe, life-threatening sepsis and venous thrombosis should be considered.</div></li><li class="half_rhythm"><div>Other complications, such as gallstones and leg ulcers, require appropriate medical or surgical treatment.</div></li></ul></div><div id="a-thal.Prevention_of_Primary_Manifestati"><h3>Prevention of Primary Manifestations</h3><p><b>Hb Bart syndrome</b></p><p>Because of the severity of Hb Bart syndrome and the risk for maternal complications during the pregnancy with a fetus with this disorder, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> and early termination of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> pregnancies is usually considered. Future studies on the functional outcomes of children with Hb Bart syndrome who have received chronic transfusion, intrauterine transfusions, and hematopoietic stem cell transplant, will allow physicians to improve the informed decision-making process for families weighing the risk-benefit profile of present treatment options.</p></div><div id="a-thal.Prevention_of_Secondary_Complicat"><h3>Prevention of Secondary Complications</h3><p><b>HbH disease</b></p><p>During febrile episodes, a clinical evaluation is recommended because of the increased risk of hemolytic/aplastic crisis (similar to G6PD deficiency, hemolysis in HbH disease can be triggered by infection or oxidative stresses).</p><p>When chronic red blood cell transfusions are instituted for individuals with HbH disease, the management should be the same as for all individuals who have been polytransfused, including use of iron chelation therapy (see <a href="/books/n/gene/b-thal/">Beta-Thalassemia</a>).</p><p>In individuals with HbH disease who are not red blood cell transfusion dependent, the only iron chelator specifically approved is deferasirox, which has been shown to be superior to placebo in reducing liver iron concentration in those older than age ten years who have beta-thalassemia intermedia, HbE/beta-thalassemia, and HbH disease [<a class="bk_pop" href="#a-thal.REF.taher.2012.970">Taher et al 2012</a>].</p><p>Regular folic acid supplementation should be recommended, as for other hemolytic anemias.</p><p>If splenectomy is required, antimicrobial prophylaxis is usually provided, at least until age five years, to decrease the risk of overwhelming sepsis caused by encapsulated organisms. Use of antimicrobial prophylaxis notwithstanding, a careful clinical evaluation of splenectomized individuals with fever is recommended.</p></div><div id="a-thal.Surveillance"><h3>Surveillance</h3><p><b>HbH disease</b></p><ul><li class="half_rhythm"><div>Hematologic evaluation every six to 12 months to determine the steady state levels of hemoglobin</div></li><li class="half_rhythm"><div>In children, assessment of growth and development every six to 12 months</div></li><li class="half_rhythm"><div>Monitoring of iron load with annual determination of serum ferritin concentration in individuals who have been transfused, in older individuals, and in those given inappropriate iron supplementation. Since serum ferritin may underestimate the degree of iron overload, a periodic quantitative measurement of liver iron concentration is also recommended [<a class="bk_pop" href="#a-thal.REF.musallam.2012.s16">Musallam et al 2012</a>].</div></li></ul></div><div id="a-thal.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>HbH disease</b></p><ul><li class="half_rhythm"><div>Inappropriate iron therapy</div></li><li class="half_rhythm"><div>Oxidant drugs including sulphonamides; some antimalarials because of the risk of hemolytic crisis</div></li></ul></div><div id="a-thal.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> should be evaluated as soon as possible after birth to determine if they have HbH disease so that appropriate monitoring can be instituted. Evaluations can include:</p><ul><li class="half_rhythm"><div>Evaluation of red blood cell indices, red blood cell supravital stain for HbH inclusions and hemoglobin analysis by HPLC</div></li><li class="half_rhythm"><div>Targeted molecular analysis if the pathogenic variants in the family are known</div></li><li class="half_rhythm"><div>Molecular genetic analysis (according to the frequency of &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> pathogenic variants in each geographic area) if the pathogenic variants in the family are not known.</div></li></ul><p>See <a href="#a-thal.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="a-thal.Pregnancy_Management"><h3>Pregnancy Management</h3><p>During pregnancy several complications have been reported in women with HbH disease, including worsening of anemia (with occasional need of red cell transfusions), preeclampsia, congestive heart failure, and threatened miscarriage [<a class="bk_pop" href="#a-thal.REF.origa.2007.326">Origa et al 2007</a>]. Monitoring for these possible complications is recommended.</p></div><div id="a-thal.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="a-thal.Genetic_Counseling"><h2 id="_a-thal_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="a-thal.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Alpha-thalassemia (&#x003b1;-thalassemia) is usually inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="a-thal.Risk_to_Family_Members__Hemoglobi"><h3>Risk to Family Members &#x02013; Hemoglobin Bart Hydrops Fetalis (Hb Bart) Syndrome</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of a fetus with Hb Bart syndrome have &#x003b1;-thalassemia trait.</div></li><li class="half_rhythm"><div>Individuals with &#x003b1;-thalassemia trait typically have mild hypochromic (low MCH), microcytic (low MCV) anemia, and normal HbA2 and HbF.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> At conception, each sib of a proband with Hb Bart syndrome has a 25% chance of having Hb Bart syndrome, a 50% chance of having &#x003b1;-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;), and a 25% chance of being unaffected and not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Hb Bart syndrome is often not compatible with postnatal life.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of having &#x003b1;-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;).</div></li><li class="half_rhythm"><div>Individuals with &#x003b1;-thalassemia trait typically have mild hypochromic (low MCH), microcytic (low MCV) anemia, and normal HbA2 and HbF.</div></li></ul></div><div id="a-thal.Risk_to_Family_Members__Hemoglobi_1"><h3>Risk to Family Members &#x02013; Hemoglobin H (HbH) Disease</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The parents of a child with HbH disease usually have different genotypes:</p><ul><li class="half_rhythm"><div>Most commonly, one parent has &#x003b1;-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) and the other parent is an &#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (1-gene deletion; -&#x003b1;/&#x003b1;&#x003b1;). Rarely, one parent has &#x003b1;-thalassemia trait with a two-gene deletion <i>in</i>
<i>cis</i> (--/&#x003b1;&#x003b1;) and the other parent is an &#x003b1;-thalassemia carrier with a non-deletion variant.</div></li><li class="half_rhythm"><div>Alternatively, though less likely, one parent has &#x003b1;-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) and the other parent has &#x003b1;-thalassemia trait with a two-gene deletion <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a> (-&#x003b1;/-&#x003b1;). These parents have a 50% chance of having offspring with HbH disease and a 50% chance of having offspring with one-gene deletion (&#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>; -&#x003b1;/&#x003b1;&#x003b1;).</div></li><li class="half_rhythm"><div>Uncommonly, both parents carry a specific <i>HBA2</i> non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> &#x003b1;-thalassemia variant (e.g., &#x003b1;<sup>T-Saudi</sup>, HBA2:c.*93_*94delAA)</div></li><li class="half_rhythm"><div>Individuals with &#x003b1;-thalassemia trait typically have mild microcytosis and normal HbA2 and HbF.</div></li><li class="half_rhythm"><div>Alpha-thalassemia silent carriers (loss of 1 &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>) are either hematologically normal or have a mild reduction of MCV and MCH.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> At conception, each sib of an individual with HbH disease whose parents have the most common variants (1 parent has --/&#x003b1;&#x003b1; and the other parent has -&#x003b1;/&#x003b1;&#x003b1;) has a 25% chance of having HbH disease, a 25% chance of having &#x003b1;-thalassemia trait with a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;), a 25% chance of being an &#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> with loss of one &#x003b1;-globin gene, and a 25% chance of being unaffected and not a carrier.</p><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with HbH disease inherits a loss of two &#x003b1;-globin genes <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (&#x003b1;-thalassemia trait) or a loss of one &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (&#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) and is thus an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a>.</div></li><li class="half_rhythm"><div>Given the high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> of &#x003b1;-thalassemia in certain populations, it is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> to the reproductive partner of an individual with &#x003b1;-thalassemia trait with a loss of two &#x003b1;-globin genes <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;).</div></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with either Hb Bart syndrome or HbH disease.</b> Each sib of the proband's parents is at risk of having loss of one &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (&#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) and/or &#x003b1;-thalassemia trait with a loss of two &#x003b1;-globin genes <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;).</p></div><div id="a-thal.Carrier_Detection"><h3>Carrier Detection</h3><p>Individuals who should be considered for <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a>:</p><ul><li class="half_rhythm"><div>Family members</div></li><li class="half_rhythm"><div>Members of ethnic groups at risk (see <a href="#a-thal.Prevalence">Prevalence</a>)</div></li><li class="half_rhythm"><div>Gamete donors for assisted reproductive technologies (ART)</div></li></ul><p><b>Alpha-thalassemia trait</b> is associated with a moderate, thalassemia-like hematologic picture (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_alpha/?report=objectonly" target="object" rid-figpopup="figathalTredbloodcellindicesinalpha" rid-ob="figobathalTredbloodcellindicesinalpha">Table 4</a>). Identification relies on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the &#x003b1;-globin genes, <i>HBA1</i> and <i>HBA2</i> (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figathalTmoleculargenetictestingused" rid-ob="figobathalTmoleculargenetictestingused">Table 3</a>).</p><p><b>Alpha-thalassemia silent carriers</b> may have normal hematologic findings or may have a moderate, thalassemia-like hematologic picture similar to individuals with &#x003b1;-thalassemia trait (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_alpha/?report=objectonly" target="object" rid-figpopup="figathalTredbloodcellindicesinalpha" rid-ob="figobathalTredbloodcellindicesinalpha">Table 4</a>). Identification relies on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the &#x003b1;-globin genes, <i>HBA1</i> and <i>HBA2</i> (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figathalTmoleculargenetictestingused" rid-ob="figobathalTmoleculargenetictestingused">Table 3</a>).</p><div id="a-thal.T.red_blood_cell_indices_in_alpha" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Red Blood Cell Indices in Alpha-Thalassemia Trait and Silent Carrier</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.T.red_blood_cell_indices_in_alpha/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.T.red_blood_cell_indices_in_alpha_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_1" style="text-align:left;vertical-align:middle;">Red Blood Cell Indices</th><th id="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Normal</th><th id="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Carrier&#x000a0;<sup>1</sup></th></tr><tr><th headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2" id="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Male</th><th headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2" id="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Female</th><th headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3" id="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alpha-Thalassemia Trait&#x000a0;<sup>2</sup><br />(--/&#x003b1;&#x003b1; or -&#x003b1;/-&#x003b1;)</th><th headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3" id="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alpha-Thalassemia Silent Carrier<br />(-&#x003b1;/&#x003b1;&#x003b1;)</th></tr></thead><tbody><tr><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mean corpuscular volume (MCV, fl)</b></td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">89.1&#x000b1;5.01</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">87.6&#x000b1;5.5</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">71.6&#x000b1;4.1</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">81.2&#x000b1;6.9</td></tr><tr><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mean corpuscular hemoglobin (MCH, pg)</b></td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30.9&#x000b1;1.9</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30.2&#x000b1;2.1</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">22.9&#x000b1;1.3</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">26.2&#x000b1;2.3</td></tr><tr><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hemoglobin (Hb, g/dL)</b></td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15.9&#x000b1;1.0</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_2 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14.0&#x000b1;0.9</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Male: 13.9&#x000b1;1.7<br />Female: 12.0&#x000b1;1.0</td><td headers="hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_1_3 hd_h_a-thal.T.red_blood_cell_indices_in_alpha_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Male: 14.3&#x000b1;1.4<br />Female: 12.6&#x000b1;1.2</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="a-thal.TF.4.1"><p class="no_margin"><a class="bk_pop" href="#a-thal.REF.higgs.2001_1">Higgs &#x00026; Bowden [2001]</a></p></div></dd></dl></div></div></div><p>2. Alpha-thalassemia carriers with the two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;) have slightly lower RBC indices.</p><p><b>Qualitative and quantitative hemoglobin (Hb) analysis</b> (by cellulose acetate electrophoresis, weak-cation high-performance liquid chromatography [HPLC], and supplemental techniques such as <a class="def" href="/books/n/gene/glossary/def-item/isoelectric-focusing/">isoelectric focusing</a> and citrate agar electrophoresis) identifies the amount and type of Hb present (<a class="figpopup" href="/books/NBK1435/table/a-thal.T.hemoglobin_patterns_in_alphatha_1/?report=objectonly" target="object" rid-figpopup="figathalThemoglobinpatternsinalphatha1" rid-ob="figobathalThemoglobinpatternsinalphatha1">Table 5</a>).</p><ul><li class="half_rhythm"><div>Hemoglobin A (HbA). Two &#x003b1;-globin chains and two &#x003b2;-globin chains (&#x003b1;<sub>2</sub>&#x003b2;<sub>2</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin F (HbF). Two &#x003b1;-globin chains and two &#x003b3;-globin chains (&#x003b1;<sub>2</sub>&#x003b3;<sub>2</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin H (HbH). Four &#x003b2;-globin chains (&#x003b2;<sub>4</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin A2 (HbA2). Two &#x003b1;-globin chains and two &#x003b4;-globin chains (&#x003b1;<sub>2</sub>&#x003b4;<sub>2</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin Bart (Hb Bart). Four &#x003b3;-globin chains (&#x003b3;<sub>4</sub>)</div></li><li class="half_rhythm"><div>Hemoglobin Portland. Two &#x003b6;-globin chains and two &#x003b3;-globin chains (&#x003b6;<sub>2</sub>&#x003b3;<sub>2</sub>)</div></li></ul><div id="a-thal.T.hemoglobin_patterns_in_alphatha_1" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Hemoglobin Patterns in Alpha-Thalassemia Trait and Silent Carrier</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.T.hemoglobin_patterns_in_alphatha_1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.T.hemoglobin_patterns_in_alphatha_1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemoglobin Type</th><th id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</th><th id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alpha-Thalassemia Trait&#x000a0;<sup>1</sup><br />(--/&#x003b1;&#x003b1; or -&#x003b1;/-&#x003b1;)</th><th id="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alpha-Thalassemia Silent Carrier&#x000a0;<sup>2</sup><br />(-&#x003b1;/&#x003b1;&#x003b1;)</th></tr></thead><tbody><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>HbA</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%-98%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%-98%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%-98%</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>HbF</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1.0%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1.0%</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>HbH</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>HbA2</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-3%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1.5%-3.0%</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-3%</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hb Bart</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td></tr><tr><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hb Portland</b></td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_a-thal.T.hemoglobin_patterns_in_alphatha_1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="a-thal.TF.5.1"><p class="no_margin">Deletion or inactivation of two &#x003b1;-globin genes either in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration (--/&#x003b1;&#x003b1;) or in <a class="def" href="/books/n/gene/glossary/def-item/trans/"><i>trans</i></a> configuration (-&#x003b1;/-&#x003b1;)</p></div></dd><dt>2. </dt><dd><div id="a-thal.TF.5.2"><p class="no_margin">Deletion or inactivation of one &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (-&#x003b1;/&#x003b1;&#x003b1;)</p></div></dd></dl></div></div></div></div><div id="a-thal.Population_Screening"><h3>Population Screening</h3><p><b>Alpha-thalassemia trait with a loss of two</b>
<b>&#x003b1;-globin genes <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;).</b> Because of the high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> for the two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<i>cis</i> (--/&#x003b1;&#x003b1;) in certain populations and the availability of <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>, it is ideal to screen (prior to or early in pregnancy) couples who are members of at-risk populations to identify those at risk of conceiving a fetus with Hb Bart syndrome:</p><p>If both members of a couple are carriers of an &#x003b1;&#x000ba;-thalassemia <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variant (e.g., <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> --<sup>SEA</sup>/&#x003b1;&#x003b1;), all of their offspring have a 1/4 risk of having Hb Bart syndrome.</p><p>If both members of the couple are carriers of the &#x003b1;&#x000ba;-thalassemia <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variant in which both <i>HBA1</i> and <i>HBA2</i> as well as <i>HBZ</i> are deleted (i.e., <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> &#x02013;<sup>FIL</sup>/&#x003b1;&#x003b1; or genotype &#x02013;<sup>THAI</sup>/&#x003b1;&#x003b1;), they are not at risk of having offspring with Hb Bart syndrome because homozygotes for such pathogenic variants are lost shortly after conception.</p><p>If both members of the couple are carriers of a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> involving both <i>HBA1</i> and <i>HBA2</i>, but only one of them has a deletion that extends into <i>HBZ</i> (e.g., a couple with genotypes &#x02013;<sup>SEA</sup>/&#x003b1;&#x003b1; and &#x02013;<sup>FIL</sup>/&#x003b1;&#x003b1;), the couple is at risk of having offspring with Hb Bart syndrome because the single <i>HBZ</i> in the fetus produces sufficient &#x003b6;-globin for fetal development [<a class="bk_pop" href="#a-thal.REF.chui.1998.2213">Chui &#x00026; Waye 1998</a>].</p><p><b>Alpha-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</b> Prospective identification of &#x003b1;-thalassemia silent carriers is not strongly indicated, as the offspring of these carriers are not at risk for Hb Bart syndrome.</p></div><div id="a-thal.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#a-thal.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who have HbH disease, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="a-thal.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>High-risk pregnancies.</b> Prenatal testing is possible for couples confirmed by DNA analysis to be at risk of having a fetus with Hb Bart syndrome because both parents are carriers of a two-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (--/&#x003b1;&#x003b1;). Molecular genetic testing can be performed either on fetal DNA extracted from cells obtained by chorionic villus sampling or by amniocentesis.</p><p><b>Ultrasound examination.</b> Ultrasonography can also be useful in the management of pregnancies at risk for Hb Bart syndrome. In the first trimester, increased nuchal thickness, particularly in an at-risk pregnancy, should prompt appropriate evaluation.</p><p><b>Indeterminate-risk pregnancies.</b> An indeterminate-risk pregnancy is a pregnancy for which ONE of the following is true:</p><ul><li class="half_rhythm"><div>One parent has &#x003b1;-thalassemia trait with a loss of two &#x003b1;-globin genes <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (e.g., --/&#x003b1;&#x003b1;) and the other has an &#x003b1;-thalassemia-like hematologic picture but no &#x003b1;-thalassemia variant identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div>The mother has known &#x003b1;-thalassemia trait with a loss of two &#x003b1;-globin genes <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> (e.g., --/&#x003b1;&#x003b1;) and the father is unknown or unavailable for testing. This is of concern if the father belongs to a population with a high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> for &#x003b1;-thalassemia <a class="figpopup" href="/books/NBK1435/table/a-thal.T.selected_hba1_and_hba2_pathogen/?report=objectonly" target="object" rid-figpopup="figathalTselectedhba1andhba2pathogen" rid-ob="figobathalTselectedhba1andhba2pathogen">pathogenic variants</a>.</div></li></ul><p>In both cases, the options for prenatal testing should be discussed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>. In such cases, the strategy is fetal DNA analysis for the known &#x003b1;-thalassemia variant; if the known &#x003b1;-thalassemia variant is present, globin chain synthesis analysis is performed using a fetal blood sample obtained by percutaneous umbilical blood sampling (PUBS).</p><p><b>Preimplantation genetic diagnosis (PGD)</b> may be an option for some families in which the pathogenic variants have been identified.</p></div></div><div id="a-thal.Resources"><h2 id="_a-thal_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Cooley's Anemia Foundation</b></div><div>330 Seventh Avenue</div><div>#200</div><div>New York NY 10001</div><div><b>Phone:</b> 212-279-8090</div><div><b>Fax:</b> 212-279-5999</div><div><a href="http://cooleysanemia.org/updates/AlphaEnglish.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alpha Thalassemia (PDF file)</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Alpha-thalassemia&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alpha-thalassemia</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22200/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Thalassemia</a></div></li><li class="half_rhythm"><div><b>Thalassaemia International Federation (TIF)</b></div><div>PO Box 28807</div><div> Nicosia 2083</div><div>Cyprus</div><div><b>Phone:</b> +357 22 319129</div><div><b>Fax:</b> +357 22 314552</div><div><b>Email:</b> thalassaemia@cytanet.com.cy</div><div><a href="http://www.thalassaemia.org.cy" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.thalassaemia.org.cy</a></div></li></ul></div><div id="a-thal.Molecular_Genetics"><h2 id="_a-thal_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="a-thal.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Alpha-Thalassemia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_a-thal.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_a-thal.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_a-thal.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_a-thal.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_a-thal.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_a-thal.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_a-thal.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3039" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HBA1</i></a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3039" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P69905" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemoglobin subunit alpha</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/HBA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBA1 @ LOVD</a><br /><a href="http://globin.cse.psu.edu/globin/hbvar/menu.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HbVar: A Database of Human Hemoglobin Variants and Thalassemias (HBA1)</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HBA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBA1</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HBA1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBA1</a></td></tr><tr><td headers="hd_b_a-thal.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3040" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HBA2</i></a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3040" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P69905" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemoglobin subunit alpha</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/HBA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBA2 @ LOVD</a><br /><a href="http://globin.cse.psu.edu/globin/hbvar/menu.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HbVar: A Database of Human Hemoglobin Variants and Thalassemias (HBA2)</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HBA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBA2</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HBA2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBA2</a></td></tr><tr><td headers="hd_b_a-thal.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3050" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HBZ</i></a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3050" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P02008" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemoglobin subunit zeta</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://globin.cse.psu.edu/globin/hbvar/menu.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HbVar: A Database of Human Hemoglobin Variants and Thalassemias (HBZ)</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HBZ" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBZ</a></td><td headers="hd_b_a-thal.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HBZ[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HBZ</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="a-thal.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="a-thal.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Alpha-Thalassemia (<a href="/omim/141800,141850,142310,604131" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/141800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">141800</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOGLOBIN--ALPHA LOCUS 1; HBA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/141850" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">141850</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOGLOBIN--ALPHA LOCUS 2; HBA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/142310" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">142310</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOGLOBIN--ZETA LOCUS; HBZ</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604131" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604131</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALPHA-THALASSEMIA</td></tr></tbody></table></div></div><div id="a-thal.HBA1_HBA2_and_HBZ"><h3><i>HBA1</i>, <i>HBA2</i>, and <i>HBZ</i></h3><p>Alpha-globin genes are duplicated (<i>HBA1</i> and <i>HBA2</i>) and lie in the telomeric region of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 16 (16p13.3) within a cluster that also contains an embryonic &#x003b1;-like <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>HBZ</i>), and two pseudogenes (<i>HBZP</i> [&#x003c8;-&#x003b6;] and <i>HBAP1</i> [&#x003c8;-&#x003b1;<sub>1</sub>]). <i>HBD</i> (&#x003c8;-&#x003b1;<sub>2</sub>), previously considered a <a class="def" href="/books/n/gene/glossary/def-item/pseudogene/">pseudogene</a>, was recently demonstrated to produce <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>, although a very little amount [<a class="bk_pop" href="#a-thal.REF.goh.2005.1466">Goh et al 2005</a>]. A &#x003b8; gene (<i>HBQ1</i>) with an unknown function is located at the 5' end of the cluster (see <a class="figpopup" href="/books/NBK1435/figure/a-thal.F2/?report=objectonly" target="object" rid-figpopup="figathalF2" rid-ob="figobathalF2">Figure 2</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figathalF2" co-legend-rid="figlgndathalF2"><a href="/books/NBK1435/figure/a-thal.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figathalF2" rid-ob="figobathalF2"><img class="small-thumb" src="/books/NBK1435/bin/a-thal-Image002.gif" src-large="/books/NBK1435/bin/a-thal-Image002.jpg" alt="Figure 2. . Diagram of the &#x003b1;-globin gene cluster." /></a><div class="icnblk_cntnt" id="figlgndathalF2"><h4 id="a-thal.F2"><a href="/books/NBK1435/figure/a-thal.F2/?report=objectonly" target="object" rid-ob="figobathalF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Diagram of the &#x003b1;-globin gene cluster. In order from centromere to telomere, the genes include: &#x003b1;1 (<i>HBA1</i>, encoding &#x003b1;1-globin); &#x003b1;2 (<i>HBA2</i>, encoding &#x003b1;2-globin); &#x003c8;&#x003b1;1, <i>HBD</i> (previously called &#x003c8;&#x003b1;2), <a href="/books/NBK1435/figure/a-thal.F2/?report=objectonly" target="object" rid-ob="figobathalF2">(more...)</a></p></div></div><p><i>HBA1</i> and <i>HBA2</i> are embedded within two markedly homologous regions that extend for approximately 4 kb. Their sequence homology is maintained by <a class="def" href="/books/n/gene/glossary/def-item/gene-conversion/">gene conversion</a> and unequal crossover events. In this DNA region, three highly homologous segments, named X, Y, and Z, separated by non-homologous segments, have been defined (see <a class="figpopup" href="/books/NBK1435/figure/a-thal.F2/?report=objectonly" target="object" rid-figpopup="figathalF2" rid-ob="figobathalF2">Figure 2</a>).</p><p>As a result of unequal genetic exchange, individuals who are phenotypically normal may have four, five, or six &#x003b1;-globin genes and two to six <i>HBZ</i>-like genes. <i>HBA</i>-like globin genes are arranged in the cluster in the order in which they are expressed during development. The genes encoding the &#x003b1;<sub>1</sub>-globin chain <i>(HBA1</i>) and the &#x003b1;<sub>2</sub>-globin chain <i>(HBA2</i>) display a marked homology resulting from repeated rounds of <a class="def" href="/books/n/gene/glossary/def-item/gene-conversion/">gene conversion</a>.</p><p>The level of transcription of the two genes differs, as <i>HBA2</i> produces two to three times more &#x003b1;-globin than <i>HBA1</i>. Regarding the translation profile of <i>HBA1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and <i>HBA2</i> mRNA, contrasting results in which percentages of <i>HBA2</i> mRNA are higher or only slightly higher than percentages of <i>HBA1</i> mRNA have been reported. The different expression of the two &#x003b1;-globin genes has important clinical implications for the amount of structural &#x003b1;-variant resulting from inactivation of <i>HBA1</i> or <i>HBA2</i>, and for the pathophysiology of the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> and non-deletion pathogenic variants of <i>HBA1</i> and <i>HBA2</i>.</p><p>The expression of <i>HBA1</i> and <i>HBA2</i> is regulated by a region (HS-40) located 40 kb upstream from the &#x003b1;-globin cluster (<a class="figpopup" href="/books/NBK1435/figure/a-thal.F2/?report=objectonly" target="object" rid-figpopup="figathalF2" rid-ob="figobathalF2">Figure 2</a>). This region contains multiple binding sites for transcriptional factors (NF-E2, GATA-1). The <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of HS-40 results in an &#x003b1;-thalassemia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, in spite of the structural integrity of both &#x003b1;-globin genes.</p><div id="a-thal.Gene_Structure"><h4>Gene Structure</h4><p>Both <i>HBA1</i> and <i>HBA2</i> have three coding exons. The mRNAs produced by <i>HBA1</i> and <i>HBA2</i> have identical coding regions and can be distinguished only by their 3' UTR. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1435/#a-thal.molgen.TA">Table A</a>, <b>Gene</b>.</p></div><div id="a-thal.Pathogenic_Variants"><h4>Pathogenic Variants</h4><p>See <a class="figpopup" href="/books/NBK1435/table/a-thal.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figathalTmoleculargenetictestingused" rid-ob="figobathalTmoleculargenetictestingused">Table 3</a>. Deletion of <i>HBA1</i> and/or <i>HBA2</i> is the most common cause of &#x003b1;-thalassemia.</p><p><b>Deletion of two &#x003b1;-goblin genes <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a>.</b> Different deletions varying from approximately 6 kb to more than 300 kb and removing both &#x003b1;-globin genes <i>(HBA1</i> and <i>HBA2</i>) (and sometimes the embryonic <i>HBZ</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>) result in the complete absence of &#x003b1;-chain production from that <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Most of these deletions are founder variants that arose by one of several molecular mechanisms, including illegitimate <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a>, reciprocal <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a>, and truncation of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 16. More than 20 different &#x003b1;&#x000ba;-thalassemia deletions have been reported to date:</p><ul><li class="half_rhythm"><div>The most common alleles are the Southeast Asian (--<sup>SEA</sup>) and the Filipino (--<sup>FIL</sup>) types.</div></li><li class="half_rhythm"><div>Two <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> alleles, -(&#x003b1;)<sup>5.2</sup> and -(&#x003b1;)<sup>20.5</sup>, remove <i>HBA2</i> and part of <i>HBA1</i> [<a class="bk_pop" href="#a-thal.REF.higgs.2001">Higgs 2001</a>].</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> removing <i>HBA1</i> and the theta <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>HBQ1</i>) extends downstream centromeric from the &#x003b1;-globin gene cluster. The silencing of intact <i>HBA2</i> in this <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> is related to an antisense RNA transcribed from the widely expressed <i>LUC7L</i>, becoming juxtaposed to the normal <i>HBA2</i> by the deletion, and running through the <i>HBA2</i> sequences [<a class="bk_pop" href="#a-thal.REF.tufarelli.2003.157">Tufarelli et al 2003</a>].</div></li><li class="half_rhythm"><div>Several deletions of the HS-40 region also result in the silencing of the intact &#x003b1;-globin genes [<a class="bk_pop" href="#a-thal.REF.higgs.2001">Higgs 2001</a>, <a class="bk_pop" href="#a-thal.REF.coelho.2010.147">Coelho et al 2010</a>, <a class="bk_pop" href="#a-thal.REF.sollaino.2010.2193">Sollaino et al 2010</a>, <a class="bk_pop" href="#a-thal.REF.wu.2017.984">Wu et al 2017</a>].</div></li></ul><p><b>Deletion of one &#x003b1;-goblin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</b> Reciprocal <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> between the Z boxes, which are 3.7 kb apart, or between the X boxes, 4.2 kb apart, gives rise to chromosomes with a single &#x003b1;-globin gene. The two resulting &#x003b1;-thalassemia variants are referred to respectively as the 3.7-kb rightward <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (-&#x003b1;<sup>3.7</sup>) and the 4.2-kb leftward deletion (-&#x003b1;<sup>4.2</sup>) (see <a class="figpopup" href="/books/NBK1435/figure/a-thal.F2/?report=objectonly" target="object" rid-figpopup="figathalF2" rid-ob="figobathalF2">Figure 2</a>):</p><ul><li class="half_rhythm"><div>In relation to the location of the crossover within the Z box, the -&#x003b1;<sup>3.7</sup> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> is subdivided into three varieties named I, II, and III.</div></li><li class="half_rhythm"><div>In addition to the -&#x003b1;<sup>3.7</sup> and the -&#x003b1;<sup>4.2</sup> common alleles, other rare deletions involving a single &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been reported.</div></li><li class="half_rhythm"><div>These <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> events also result in the production of chromosomes containing three &#x003b1;-globin genes. A triplicated &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> inherited with <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> &#x003b2;-thalassemia results in a mild thalassemia intermedia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li></ul><p><b>Non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> &#x003b1;-thalassemia.</b> Less frequently, &#x003b1;-thalassemia results from single-nucleotide variants or oligonucleotide <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>/deletion in regions critical for &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression. In non-deletion &#x003b1;-thalassemia, the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> gene is denoted T (e.g., &#x003b1;<sup>T-Saudi</sup>). Considered as a group, the non-deletion &#x003b1;-thalassemia variants appear to have a more severe effect on &#x003b1;-globin gene expression and hematologic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> than single &#x003b1;-globin-gene deletions. This phenomenon may be explained by the majority of the variants affecting <i>HBA2</i>, whose expression may predominate over <i>HBA1</i> [<a class="bk_pop" href="#a-thal.REF.higgs.2001">Higgs 2001</a>]. No compensatory increase in expression in the remaining functional &#x003b1; gene occurs when the other is inactivated by a <a class="def" href="/books/n/gene/glossary/def-item/single-nucleotide-variant/">single-nucleotide variant</a>, in contrast to the compensatory increase in expression in the remaining functional &#x003b1; gene when a single &#x003b1;-globin gene is deleted (e.g., the - &#x003b1;<sup>3.7</sup> deletion).</p><p>At present, more than 70 well-defined causes of non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> &#x003b1;-thalassemia are listed in the public <a href="http://www.hgmd.cf.ac.uk/ac/index.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGMD</a>.</p><p>The molecular mechanisms leading to the silencing of either <i>HBA1</i> or <i>HBA2</i> include: variants involving RNA <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>, the polyadenylation signal, the initiation of <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> translation, as well as <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants of the termination, <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions, frame-shift variants, and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants. Variants of &#x003b1;-globin genes that result in the production of hyper-unstable globin variants such as Hb<sup>Quong Sze</sup> and that are unable to assemble into stable &#x003b2;<sub>4</sub> tetramers and are thus rapidly degraded, may also result in &#x003b1;-thalassemia (see <a class="figpopup" href="/books/NBK1435/table/a-thal.T.selected_hba1_and_hba2_pathogen/?report=objectonly" target="object" rid-figpopup="figathalTselectedhba1andhba2pathogen" rid-ob="figobathalTselectedhba1andhba2pathogen">Table 6</a>) [<a class="bk_pop" href="#a-thal.REF.higgs.2001">Higgs 2001</a>].</p><p>The most common non-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> variant, which is frequently seen in Southeast Asia, is Hb<sup>Constant Spring</sup> (Hb<sup>CS</sup>), resulting from a nucleotide change in the stop codon of <i>HBA2</i>. This variant leads to the production of an &#x003b1;-globin chain elongated by 31 amino acids. Hb<sup>CS</sup> is produced in very small amounts because its <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is unstable. Heterozygotes for Hb<sup>CS</sup> and other rare elongated variants, along with the presence of the Hb variant, result in &#x003b1;-thalassemia trait.</p><p>Some of the variants causing &#x003b1;-chain structural variants may occur in a <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> with only one &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (e.g., Hb<sup>Q-Thailand</sup>, Hb<sup>G-Philadelphia</sup>). For more information, see <a href="/books/NBK1435/#a-thal.molgen.TA">Table A</a>.</p><div id="a-thal.T.selected_hba1_and_hba2_pathogen" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Selected <i>HBA1</i> and <i>HBA2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1435/table/a-thal.T.selected_hba1_and_hba2_pathogen/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-thal.T.selected_hba1_and_hba2_pathogen_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change&#x000a0;<sup>1</sup></th><th id="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change&#x000a0;<sup>1,&#x000a0;2</sup><br />(Conventional Nomenclature&#x000a0;<sup>3</sup>)</th><th id="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common Name<sup>2</sup></th><th id="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: c.2T&#x0003e;C</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: p.Met1Thr</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b1;<sup>NcoI</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_4" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;val=NM_000517.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000517<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;id=4504345" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000508<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: c.377T&#x0003e;C</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: p.Leu126Pro<br />(Alpha2 Leu125Pro)</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hb<sup>Quong Sze</sup></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: c.427T&#x0003e;C</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: p.Ter143Glnext32<br />(Alpha2 142, Stop&#x0003e;Gln)</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hb<sup>Constant Spring</sup> (Hb<sup>CS</sup>)</td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: c.94_95delAG</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: p.Arg32AspfsTer24<br />(The <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of 2 nucleotides causes a frameshift &#x00026; premature termination at codon [TAA])</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: c.[339C&#x0003e;G; 340_351delCTCCCCGCCGAG]</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: p.[His113Gln; Leu114_Glu117del]<br />(Alpha2 His112Gln <i>and</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of codons 113-116 -Leu-Pro-Ala-Glu)</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hb<sup>Lleida</sup></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: c.95+2_95+6delTGAGG</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b1;<sup>HphI</sup></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA1</i>: c.223G&#x0003e;C</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA1</i>: p.Asp75Gly<br />(Asp74Gly)</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hb<sup>Q-Thailand</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=14456711" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000558<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;val=4504347" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000549<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: c.207C&#x0003e;G<br />or <i>HBA1</i>: 207C&#x0003e;A</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i> or <i>HBA1</i>: p.Asn69Lys<br />(Asn68Lys)</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hb<sup>G-Philadelphia</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;val=NM_000517.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000517<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;id=4504345" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000508<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2</i>: c.*94A&#x0003e;G</td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x003b1;<sup>T-Saudi</sup></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HBA2:</i> c.[-2_-3delAC; -&#x003b1;<sup>3.7</sup>]&#x000a0;<sup>4</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i> and of nucleotides that additionally impair translation of the remaining <i>HBA1</i></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-&#x003b1;<sup>3.7</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_4" rowspan="8" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=1817575" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Z84721<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-&#x003b1;<sup>4.2</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-(&#x003b1;)<sup>5.2</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i> and 5' end of <i>HBA1</i>&#x000a0;<sup>5</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-(&#x003b1;)<sup>20.5</sup><br />(g.15164_37864del22701)&#x000a0;<sup>6</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i> and 5' end of <i>HBA1</i></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02212;&#x02212;<sup>FIL</sup><br />(g.11684_43534del31851)&#x000a0;<sup>6</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i> and <i>HBA1</i></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02212;&#x02212;<sup>MED</sup><br />(g.24664_41064del16401)&#x000a0;<sup>6</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i> and <i>HBA1</i></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02212;&#x02212;<sup>SEA</sup><br />(g.26264_45564del19301)&#x000a0;<sup>6</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i> and <i>HBA1</i></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02212;&#x02212;<sup>THAI</sup><br />(g.10664_44164del33501)&#x000a0;<sup>6</sup></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deletion of <i>HBA2</i> and <i>HBA1</i></td><td headers="hd_h_a-thal.T.selected_hba1_and_hba2_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt>1. </dt><dd><div id="a-thal.TF.6.1"><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>2. </dt><dd><div id="a-thal.TF.6.2"><p class="no_margin">Only functional globin genes involved in the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> are given; deleted pseudogenes are not listed.</p></div></dd><dt>3. </dt><dd><div id="a-thal.TF.6.3"><p class="no_margin">Globin variants are given by their conventional nomenclature (<a href="http://globin.cse.psu.edu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">globin<wbr style="display:inline-block"></wbr>​.cse.psu.edu</a>).</p></div></dd><dt>4. </dt><dd><div id="a-thal.TF.6.4"><p class="no_margin">Denotes two variations in one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>: <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of AC at -2 and -3 before ATG initiation codon in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration on an -&#x003b1;<sup>3.7</sup> deletion allele [<a class="bk_pop" href="#a-thal.REF.viprakasit.2003.133">Viprakasit et al 2003</a>]</p></div></dd><dt>5. </dt><dd><div id="a-thal.TF.6.5"><p class="no_margin"><a class="bk_pop" href="#a-thal.REF.pressley.1980.4889">Pressley et al [1980]</a></p></div></dd><dt>6. </dt><dd><div id="a-thal.TF.6.6"><p class="no_margin">Coordinates from entries in the <a href="http://globin.cse.psu.edu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Globin Gene Server</a>; it is not known if all deletions in these categories will have precisely the same nucleotide coordinates.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The &#x003b1;-globin chains produced by HBA1 and HBA2 mRNAs have identical amino acid sequences. The heterodimer protein hemoglobin A is made up of two &#x003b1; chains and two &#x003b2; chains.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The consequence of a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of one &#x003b1;-globin gene is reduced production of &#x003b1;-globin chains by the affected <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> (&#x003b1;-thalassemia silent <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>; -&#x003b1;/&#x003b1;&#x003b1;). For example, measurement of &#x003b1;-globin <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> indicates that the -&#x003b1;<sup>4.2</sup> variant is not associated with a compensatory increase in expression in the remaining <i>HBA1</i>, whereas with the -&#x003b1;<sup>3.7</sup> variant, the remaining <i>HBA1</i> expression is roughly halfway between that of normal <i>HBA2</i> and <i>HBA1</i> (see <a class="figpopup" href="/books/NBK1435/figure/a-thal.F2/?report=objectonly" target="object" rid-figpopup="figathalF2" rid-ob="figobathalF2">Figure 2</a>).</p></div></div></div><div id="a-thal.References"><h2 id="_a-thal_References_">References</h2><div id="a-thal.Published_Guidelines__Consensus_S"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.acog_committee_on_obstetrics.2007.229">ACOG Committee on Obstetrics.  ACOG Practice Bulletin No. 78: Hemoglobinopathies in pregnancy. <span><span class="ref-journal">Obstet Gynecol. </span>2007;<span class="ref-vol">109</span>:229–37.</span> [<a href="/pubmed/17197616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17197616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.fucharoen.2009">Fucharoen S, Viprakasit V. Hb H disease: clinical course and disease modifiers. Available <a href="http://asheducationbook.hematologylibrary.org/content/2009/1/26.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2009. Accessed 8-20-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.taher.2013">Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. <em>Guidelines for the Management of Non Transfusion Dependent Thalassaemia</em>. Weatherall D, ed. Thalassaemia International Federation. Available <a href="https://www.ncbi.nlm.nih.gov/books/NBK190453/" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 8-20-18.</div></li></ul></div><div id="a-thal.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.amid.2016.1208">Amid A, Chen S, Brien W, Kirby-Allen M, Odame I. Optimizing chronic transfusion therapy for survivors of hemoglobin Barts hydrops fetalis. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">127</span>:1208–11.</span> [<a href="/pubmed/26732098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26732098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.chui.2003.791">Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">101</span>:791–800.</span> [<a href="/pubmed/12393486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12393486</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.chui.1998.2213">Chui DH, Waye JS. Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. <span><span class="ref-journal">Blood. </span>1998;<span class="ref-vol">91</span>:2213–22.</span> [<a href="/pubmed/9516118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9516118</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.coelho.2010.147">Coelho A, Pican&#x000e7;o I, Seuanes F, Seixas MT, Faustino P. Novel large deletions in the human alpha-globin gene cluster: Clarifying the HS-40 long-range regulatory role in the native chromosome environment. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2010;<span class="ref-vol">45</span>:147–53.</span> [<a href="/pubmed/20580289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20580289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.de_gobbi.2006.1215">De Gobbi M, Viprakasit V, Hughes JR, Fisher C, Buckle VJ, Ayyub H, Gibbons RJ, Vernimmen D, Yoshinaga Y, de Jong P, Cheng JF, Rubin EM, Wood WG, Bowden D, Higgs DR. A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. <span><span class="ref-journal">Science. </span>2006;<span class="ref-vol">312</span>:1215–7.</span> [<a href="/pubmed/16728641" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16728641</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.fucharoen.2009.26">Fucharoen S, Viprakasit V. Hb H disease: clinical course and disease modifiers. <span><span class="ref-journal">Hematology Am Soc Hematol Educ Program. </span>2009:26–34.</span> [<a href="/pubmed/20008179" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20008179</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.galanello.1992.1">Galanello R, Aru B, Dess&#x000ec; C, Addis M, Paglietti E, Melis MA, Cocco S, Massa P, Giagu N, Barella S, Turco MP, Maccioni L, Cao A. HbH disease in Sardinia: molecular, hematological and clinical aspects. <span><span class="ref-journal">Acta Haematol. </span>1992;<span class="ref-vol">88</span>:1–6.</span> [<a href="/pubmed/1414154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1414154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.gibbons.2003.446">Gibbons RJ, Pellagatti A, Garrick D, Wood WG, Malik N, Ayyub H, Langford C, Boultwood J, Wainscoat JS, Higgs DR. Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS). <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">34</span>:446–9.</span> [<a href="/pubmed/12858175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12858175</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.gibson.2008.225">Gibson WT, Harvard C, Qiao Y, Somerville MJ, Lewis ME, Rajcan-Separovic E. Phenotype-genotype characterization of alpha-thalassemia mental retardation syndrome due to isolated monosomy of 16p13.3. <span><span class="ref-journal">Am J Med Genet A. </span>2008;<span class="ref-vol">146A</span>:225–32.</span> [<a href="/pubmed/18076105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18076105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.goh.2005.1466">Goh SH, Lee YT, Bhanu NV, Cam MC, Desper R, Martin BM, Moharram R, Gherman RB, Miller JL. A newly discovered human alpha-globin gene. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>:1466–72.</span> [<a href="/pmc/articles/PMC1895206/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1895206</span></a>] [<a href="/pubmed/15855277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15855277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.harteveld.2007.283">Harteveld CL, Kriek M, Bijlsma EK, Erjavec Z, Balak D, Phylipsen M, Voskamp A, Capua E, White SJ, Giordano PC. Refinement of the genetic cause of ATR-16. <span><span class="ref-journal">Hum Genet. </span>2007;<span class="ref-vol">122</span>:283–92.</span> [<a href="/pubmed/17598130" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17598130</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.harteveld.2014.1">Harteveld CL. State of the art and new developments in molecular diagnostics for hemoglobinopathies in multiethnic societies. <span><span class="ref-journal">Int J Lab Hematol. </span>2014;<span class="ref-vol">36</span>:1–12.</span> [<a href="/pubmed/23721114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23721114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.higgs.2001">Higgs DR. Molecular mechanisms of alpha thalassemia. In: Steinberg MH, Forget PG, Higgs DR, Nagel RL, eds. <em>Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management.</em> Cambridge, UK: Cambridge University Press; 2001:405-30.</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.higgs.2001_1">Higgs DR, Bowden DK. Clinical and laboratory features of the alpha-thalassemia syndromes. In: Steinberg MH, Forget PG, Higgs DR, Nagel RL, eds. <em>Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management.</em> Cambridge, UK: Cambridge University Press; 2001:431-69.</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.lehmann.1984.552">Lehmann H, Carrell RW. Nomenclature of the alpha-thalassaemias. <span><span class="ref-journal">Lancet. </span>1984;<span class="ref-vol">1</span>:552–3.</span> [<a href="/pubmed/6199634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6199634</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.lindor.1997.451">Lindor NM, Valdes MG, Wick M, Thibodeau SN, Jalal S. De novo 16p deletion: ATR-16 syndrome. <span><span class="ref-journal">Am J Med Genet. </span>1997;<span class="ref-vol">72</span>:451–4.</span> [<a href="/pubmed/9375730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9375730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.lorey.2001.72">Lorey F, Charoenkwan P, Witkowska HE, Lafferty J, Patterson M, Eng B, Waye JS, Finklestein JZ, Chui DH. Hb H hydrops foetalis syndrome: a case report and review of literature. <span><span class="ref-journal">Br J Haematol. </span>2001;<span class="ref-vol">115</span>:72–8.</span> [<a href="/pubmed/11722414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11722414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.musallam.2012.s16">Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. <span><span class="ref-journal">Blood Rev. </span>2012;<span class="ref-vol">26</span> Suppl 1:S16–9.</span> [<a href="/pubmed/22631036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22631036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.origa.2007.326">Origa R, Sollaino MC, Giagu N, Barella S, Campus S, Mandas C, Bina P, Perseu L, Galanello R. Clinical and molecular analysis of haemoglobin H disease in Sardinia: haematological, obstetric and cardiac aspects in patients with different genotypes. <span><span class="ref-journal">Br J Haematol. </span>2007;<span class="ref-vol">136</span>:326–32.</span> [<a href="/pubmed/17129226" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17129226</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.pecker.2017.151">Pecker LH, Guerrera MF, Loechelt B, Massaro A, Abraham AA, Fasano RM, Meier ER. Homozygous &#x003b1;-thalassemia: Challenges surrounding early identification, treatment, and cure. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2017;<span class="ref-vol">64</span>:151–5.</span> [<a href="/pubmed/27573913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27573913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.piel.2014.1908">Piel FB, Weatherall DJ. The &#x003b1;-thalassemias. <span><span class="ref-journal">N Engl J Med. </span>2014;<span class="ref-vol">371</span>:1908–16.</span> [<a href="/pubmed/25390741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25390741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.pressley.1980.4889">Pressley L, Higgs DR, Aldridge B, Metaxatou-Mavromati A, Clegg JB, Weatherall DJ. Characterisation of a new alpha thalassemia 1 defect due to a partial deletion of the alpha globin gene complex. <span><span class="ref-journal">Nucleic Acids Res. </span>1980;<span class="ref-vol">8</span>:4889–98.</span> [<a href="/pmc/articles/PMC324266/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC324266</span></a>] [<a href="/pubmed/6255436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6255436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.sollaino.2010.2193">Sollaino MC, Paglietti ME, Loi D, Congiu R, Podda R, Galanello R. Homozygous deletion of the major alpha-globin regulatory element (MCS-R2) responsible for a severe case of hemoglobin H disease. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:2193–4.</span> [<a href="/pubmed/20864588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20864588</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.steensma.2005.443">Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:443–52.</span> [<a href="/pubmed/15358626" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15358626</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.steensma.2004a.2019">Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. <span><span class="ref-journal">Blood. </span>2004a;<span class="ref-vol">103</span>:2019–26.</span> [<a href="/pubmed/14592816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14592816</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.steensma.2004b.1518">Steensma DP, Viprakasit V, Hendrick A, Goff DK, Leach J, Gibbons RJ, Higgs DR. Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome. <span><span class="ref-journal">Blood. </span>2004b;<span class="ref-vol">103</span>:1518–20.</span> [<a href="/pubmed/14576055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14576055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.taher.2012.970">Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">120</span>:970–7.</span> [<a href="/pubmed/22589472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22589472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.tufarelli.2003.157">Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, Wood WG, Higgs DR. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">34</span>:157–65.</span> [<a href="/pubmed/12730694" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12730694</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.vaeusorn.1985">Vaeusorn O, Fucharoen S, Ruangpiroj T, et al. Fetal pathology and maternal morbidity in hemoglobin Bart's hydrops fetalis: an analysis of 65 cases. Bangkok, Thailand: First International Conference on Thalassemia. 1985.</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.viprakasit.2003.133">Viprakasit V, Ayyub H, May A. Dinucleotide deletion in -alpha3.7 allele causes a severe form of alpha+ thalassemia. <span><span class="ref-journal">Eur J Haematol. </span>2003;<span class="ref-vol">71</span>:133–6.</span> [<a href="/pubmed/12890155" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12890155</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-thal.REF.wu.2017.984">Wu MY, He Y, Yan JM, Li DZ. A novel selective deletion of the major &#x003b1;-globin regulatory element (MCS-R2) causing &#x003b1;-thalassemia. <span><span class="ref-journal">Br J Haematol. </span>2017;<span class="ref-vol">176</span>:984–6.</span> [<a href="/pubmed/26915575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26915575</span></a>]</div></li></ul></div></div><div id="a-thal.Chapter_Notes"><h2 id="_a-thal_Chapter_Notes_">Chapter Notes</h2><div id="a-thal.Author_Notes"><h3>Author Notes</h3><p><b>Antonio Cao, MD (1929-2012)</b></p><p>Antonio Cao, MD, Professor of Pediatrics at Cagliari University (Italy), was a world-renowned expert in the field of pediatrics and genetics. He was best known for his leadership role in understanding, diagnosing, preventing, and treating thalassemia. Among other honors, he received the Allan Award from the American Society of Human Genetics (1993) and the M&#x000e4;rta Philipson's Award for Progress in Paediatrics, given by the Karolinska Institutet, Stockholm (2000). Professor Cao was passionate about science and new discoveries, intuitive, demanding, and extremely innovative in his research; all of us in this field &#x02013; and our patients &#x02013; are deeply indebted to him for his work and his inspiration will continue to guide us in the years ahead.&#x02014; Renzo Galanello, MD</p><p><b>Renzo Galanello, MD (1948-2013)</b></p><p>Renzo Galanello, MD, Professor of Pediatrics at the University of Cagliari (Italy) was internationally recognized as an expert in the field of thalassemia, to which he contributed hundreds of papers. He was the right arm of his mentor Professor Antonio Cao in the program of thalassemia control in Sardinia. He defined the theoretic criteria, flow charts and practical actuation of the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screening for thalassemia as a prerequisite to <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a>. The efficacy of the screening, tightly linked to the development of improved methods of prenatal diagnosis, led to the near-eradication of beta-thalassemia in Sardinia, establishing a model of disease control that was adopted in numerous other countries worldwide. Lately, he was among the leading scientists in the clinical validation of novel oral chelators and diagnostic assessment of cardiac iron overload. Dr Galanello was a member of national and international scientific societies and editorial committees of hematology journals, and scientific advisor of the Thalassemia International Federation, which expressed well the sad feelings of his friends and colleagues with the following commemorative words: "Professor Galanello, you will be greatly missed, but indeed all you have left behind as a doctor and a person will never be forgotten, will remain in the books, in the literature, in our minds but very importantly in our hearts."</p></div><div id="a-thal.Author_History"><h3>Author History</h3><p>Antonio Cao, MD; Consiglio Nazionale delle Ricerche (2005-2012)<br />Renzo Galanello, MD; Ospedale Regionale Microcitemie (2005-2013)<br />Paolo Moi, MD (2013-present)<br />Raffaella Origa, MD (2013-present)</p></div><div id="a-thal.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>29 December 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 November 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 June 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 July 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 November 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>3 January 2005 (rg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1435</span><span class="label">PMID: <a href="/pubmed/20301608" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301608</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/xlmr/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/alport/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1435&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1435/?report=reader">PubReader</a></li><li><a href="/books/NBK1435/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1435" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1435" style="display:none" title="Cite this Page"><div class="bk_tt">Origa R, Moi P. Alpha-Thalassemia. 2005 Nov 1 [Updated 2016 Dec 29]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1435/pdf/Bookshelf_NBK1435.pdf">PDF version of this page</a> (583K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#a-thal.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#a-thal.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#a-thal.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#a-thal.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#a-thal.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#a-thal.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#a-thal.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#a-thal.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#a-thal.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#a-thal.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#a-thal.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#a-thal.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3043[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HBB</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3039[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HBA1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3040[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HBA2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1489186" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1489186" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1489186" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1489186" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301599" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origa R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301551" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sickle Cell Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sickle Cell Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bender MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24624460" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kalfa TA, Connor JA, Begtrup AH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31424735" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Thalassemia</a><span class="source">[StatPearls. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bajwa H, Basit H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">StatPearls. 2019 Jan</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301769" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diamond-Blackfan Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diamond-Blackfan Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Clinton C, Gazda HT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301608" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301608" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041210dd21425a25ad8245">Alpha-Thalassemia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Alpha-Thalassemia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:51:12-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C0029E0405B0100000000053601EB&amp;ncbi_session=CE8C0029E04120F1_1334SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1435%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1435&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1435/&amp;ncbi_pagename=Alpha-Thalassemia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C0029E04120F1_1334SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>